ATE393766T1 - Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen - Google Patents
Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungenInfo
- Publication number
- ATE393766T1 ATE393766T1 AT04715072T AT04715072T ATE393766T1 AT E393766 T1 ATE393766 T1 AT E393766T1 AT 04715072 T AT04715072 T AT 04715072T AT 04715072 T AT04715072 T AT 04715072T AT E393766 T1 ATE393766 T1 AT E393766T1
- Authority
- AT
- Austria
- Prior art keywords
- biaryltetrahydroisocinoline
- piperidines
- obesity
- treatment
- receptor antagonists
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- 150000003053 piperidines Chemical class 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US45079903P | 2003-02-28 | 2003-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE393766T1 true ATE393766T1 (de) | 2008-05-15 |
Family
ID=32962533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04715072T ATE393766T1 (de) | 2003-02-28 | 2004-02-26 | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7498441B2 (de) |
| EP (1) | EP1601664B1 (de) |
| JP (1) | JP4570165B2 (de) |
| CN (1) | CN1777596A (de) |
| AR (1) | AR043420A1 (de) |
| AT (1) | ATE393766T1 (de) |
| CA (1) | CA2517088A1 (de) |
| DE (1) | DE602004013427T2 (de) |
| ES (1) | ES2305735T3 (de) |
| MX (1) | MXPA05009193A (de) |
| TW (1) | TW200427679A (de) |
| WO (1) | WO2004078745A1 (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008210455A1 (en) | 2007-01-31 | 2008-08-07 | Vertex Pharmaceuticals Incorporated | 2-aminopyridine derivatives useful as kinase inhibitors |
| US8569337B2 (en) | 2008-07-23 | 2013-10-29 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| WO2010011768A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Tri-cyclic pyrazolopyridine kinase inhibitors |
| WO2010011756A1 (en) | 2008-07-23 | 2010-01-28 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2313372B1 (de) | 2008-08-06 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Aminopyridine als kinaseinhibitoren |
| AU2010245914A1 (en) | 2009-05-06 | 2011-12-15 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridines |
| MX2012008643A (es) | 2010-01-27 | 2013-02-26 | Vertex Pharma | Inhibidores de cinasas de pirazolopiridinas. |
| US9067932B2 (en) | 2010-01-27 | 2015-06-30 | Vertex Pharmaceuticals Incorporated | Pyrazolopyridine kinase inhibitors |
| EP2550272A1 (de) | 2010-01-27 | 2013-01-30 | Vertex Pharmaceuticals Incorporated | Pyrazolopyrazinkinasehemmer |
| WO2017107754A1 (zh) * | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908830A (en) | 1996-10-31 | 1999-06-01 | Merck & Co., Inc. | Combination therapy for the treatment of diabetes and obesity |
| ATE267199T1 (de) * | 1997-05-30 | 2004-06-15 | Neurosearch As | 8-azabicyclo(3,2,1)oct-2-en- und octanderivate als liganden der nicotinergen ach rezeptoren |
| EP1113007A1 (de) * | 1999-12-24 | 2001-07-04 | Pfizer Inc. | Tetrahydroisochinolin-Verbindungen zur Verwendung als Östrogen-Agonisten/-Antagonisten |
| WO2002006245A1 (en) * | 2000-07-05 | 2002-01-24 | Synaptic Pharmarceutical Corporation | Selective melanin concentrating hormone-1 (mch1) receptor antagonists and uses thereof |
| WO2002083134A1 (en) | 2001-04-12 | 2002-10-24 | Pharmacopeia, Inc. | Aryl and biaryl piperidines used as mch antagonists |
| AU2003258957A1 (en) * | 2002-06-27 | 2004-01-19 | Schering Corporation | Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
-
2004
- 2004-02-26 CN CNA2004800109047A patent/CN1777596A/zh active Pending
- 2004-02-26 TW TW093104942A patent/TW200427679A/zh unknown
- 2004-02-26 DE DE602004013427T patent/DE602004013427T2/de not_active Expired - Lifetime
- 2004-02-26 JP JP2006508855A patent/JP4570165B2/ja not_active Expired - Fee Related
- 2004-02-26 ES ES04715072T patent/ES2305735T3/es not_active Expired - Lifetime
- 2004-02-26 AT AT04715072T patent/ATE393766T1/de not_active IP Right Cessation
- 2004-02-26 US US10/788,109 patent/US7498441B2/en not_active Expired - Fee Related
- 2004-02-26 CA CA002517088A patent/CA2517088A1/en not_active Abandoned
- 2004-02-26 WO PCT/US2004/005780 patent/WO2004078745A1/en active Application Filing
- 2004-02-26 EP EP04715072A patent/EP1601664B1/de not_active Expired - Lifetime
- 2004-02-26 MX MXPA05009193A patent/MXPA05009193A/es active IP Right Grant
- 2004-02-27 AR ARP040100622A patent/AR043420A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4570165B2 (ja) | 2010-10-27 |
| MXPA05009193A (es) | 2005-10-18 |
| DE602004013427D1 (de) | 2008-06-12 |
| WO2004078745A1 (en) | 2004-09-16 |
| CA2517088A1 (en) | 2004-09-16 |
| ES2305735T3 (es) | 2008-11-01 |
| US7498441B2 (en) | 2009-03-03 |
| CN1777596A (zh) | 2006-05-24 |
| EP1601664A1 (de) | 2005-12-07 |
| AR043420A1 (es) | 2005-07-27 |
| EP1601664B1 (de) | 2008-04-30 |
| DE602004013427T2 (de) | 2009-06-04 |
| JP2006520399A (ja) | 2006-09-07 |
| US20040176355A1 (en) | 2004-09-09 |
| TW200427679A (en) | 2004-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004016992D1 (de) | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3-carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen | |
| ATE446286T1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems | |
| ATE302185T1 (de) | Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität | |
| DE60319865D1 (de) | Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen | |
| DE60204548D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| ATE519488T1 (de) | Aminopyrazin-analoga zur behandlung von glaukomen und anderen durch rho-kinase verursachten krankheiten | |
| DE60317631D1 (de) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer zur behandlung von diabetes, adipositas und dyslipidämie | |
| DE60221569D1 (de) | Acrylsulfonamidderivate zur verwendung als ccr3-antagonisten bei der behandlung von inflammatorischen und immunologischen erkrankungen | |
| ATE432924T1 (de) | 3-aminoindazole derivate und ihre verwendung zur behandlung sgk-bedingten krankheiten | |
| DE602005005810D1 (de) | Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen | |
| ATE448206T1 (de) | Benzochinazolinderivate und ihre verwendung bei der behandlung von knochenerkrankungen | |
| DE502005010499D1 (de) | Implantat zur Behandlung von Fettsucht | |
| DE602004030907D1 (de) | Zur behandlung von durch crth2 vermittelten krankheiten geeignete pyrimidinderivate | |
| DE60140377D1 (de) | Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit | |
| DE602004029833D1 (de) | VEGF-Fallen und therapeutische Verwendungen dafür | |
| DE60313297D1 (de) | Gerät zum nachweis und zur behandlung von synkope | |
| MX2007004306A (es) | Compuestos biciclicos como antagonistas del receptor de la hormona concentradora de melanina selectivos para el tratamiento de la obesidad y trastornos relacionados. | |
| DE602005020293D1 (de) | Zur behandlung von hyperproliferationserkrankungen und mit angiogenese assoziierten krankheiten geeignete pyrrolotriazinderivate | |
| ITMI20050262A1 (it) | Sostanze composizioni e metodi di trattamento dell'alopecia | |
| ATE371451T1 (de) | Duale nk1/nk3 antagonisten zur behandlung von schizophrenie | |
| ATE328879T1 (de) | Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv | |
| DE502004006617D1 (de) | Vorrichtung zur ansteuerung von personenschutzmitteln | |
| ATE393766T1 (de) | Biaryltetrahydroisochinolin-piperidine als selektive mch-rezeptor-antagonisten zur behandlung von adipositas und verwandten erkrankungen | |
| ATE499147T1 (de) | Zusammensetzungen und verfahren zur behandlung kognitiver störungen | |
| DE502004011551D1 (de) | 1,3,4-substituierte pyrazole als 5-ht rezeptor-antagonisten zur behandlung von psychosen und neurologischen störungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |